Loading
Life sciences · Journal article
Diabetes & Metabolism Journal · October 12, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Obesity is associated with impaired adipocyte metabolism driven in part by mitochondrial dysfunction.Serine/ threonine-protein kinase 3 (STK3) and STK4 promote mitophagy, leading to reduced mitochondrial mass in adipose tissue.Thus, inhibition of STK3/4 represents a potential therapeutic strategy for obesity and related metabolic disorders.Methods: Two novel STK3/STK4 inhibitors, LL-M and LL-P, were identified from a focused small-molecule library using a fluorescence-based titration assay.Their effects on STK3/4 signaling and mitophagy were evaluated in C3H10T1/2 adipocytes.In vivo efficacy was assessed in male C57BL/6J mice fed either a normal chow diet or a high-fat diet (HFD), followed by a 2-week treatment with LL-M or LL-P.Metabolic outcomes, including body weight, glucose tolerance, and energy expenditure, were assessed.Results: In adipocytes, LL-M and LL-P effectively suppressed STK3/4 signaling, reduced BCL2 interacting protein 3 (BNIP3)mediated mitophagy, and increased mitochondrial metabolic activity.In HFD-fed mice, treatment with either compound attenuated body-weight gain, improved glucose tolerance, and enhanced energy expenditure.Conclusion: Pharmacological inhibition of STK3/4 by LL-M and LL-P restores mitochondrial function through suppression of BNIP3-mediated mitophagy, leading to improved adipocyte function and metabolic outcomes.These findings support the therapeutic potential of LL-M and LL-P as small-molecule candidates for the treatment of obesity and related metabolic disorders.